Bayer’s and Janssen R&D’s cardiac drug meets primary goals sooner then expected

Bayer’s and Janssen R&D’s drug for cardiac situations has already met its primary goals in the early third phase of testing, the companies said today, which concludes the testing. 

Rivaroxaban (Xarelto) is a drug for the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD).

Owing to the magnitude of effect and the confirmation of the existing safety profile of rivaroxaban, Bayer, Janssen and the Population Health Research Institute (PHRI) will offer rivaroxaban to study participants in an open-label extension trial. The COMPASS study is the largest clinical study of rivaroxaban to date. By the time of its completion, is expected to include more than 275,000 patients in both clinical trials and real-world settings.

A complete data analysis from this study is expected to be presented at an upcoming medical meeting in 2017.